Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors

ABSTRACT: This is a single-arm phase II study of twenty-one subjects with mucinous adenocarcinoma of the colon, rectum, or appendix with prior systemic therapy with a fluoropyrimidine, oxaliplatin, and irinotecan. Treatment will consist of nivolumab 480mg every 4 weeks and ipilimumab 1mg/kg every 8 weeks until disease progression, unacceptable toxicity, or 2 years of therapy.

DISEASE(S): Adenocarcinoma,Cystadenocarcinoma,Adenocarcinoma, Mucinous,Mucinous Adenocarcinoma Of The Colon,Appendiceal Neoplasms,Mucinous Adenocarcinoma Of The Rectum

PROVIDER: 2285884 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR